FilingSEC EDGAR8-K
Charles Ryan, President of IRulya Therapeutics, to depart.
· SEC accepted
StageExecutive Departure
Filing content
President Charles Ryan will conclude his service on September 8, 2026, and is eligible for severance benefits under his existing agreement.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…